Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372205 | 0.85 | HSD17B10 (0.37) | OPRD1SLC6A4HSD17B10SIGMAR1MAPT | |
| SCHEMBL8488533 | 0.85 | PLAU (0.36) | OPRD1SLC6A4PLAUPLAURSIGMAR1 | |
| SCHEMBL28297075 | 0.83 | HSD17B10 (0.38) | OPRD1SLC6A4HSD17B10SIGMAR1LMNA | |
| SCHEMBL7317195 | 0.83 | HSD17B10 (0.38) | OPRD1SLC6A4HSD17B10SIGMAR1LMNA | |
| SCHEMBL30914551 | 0.81 | HSD17B10 (0.37) | OPRD1SLC6A4HSD17B10SIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL4230913 | 0.81 | HSD17B10 (0.37) | OPRD1SLC6A4HSD17B10SIGMAR1LMNA | |
| SCHEMBL29373160 | 0.81 | HSD17B10 (0.37) | OPRD1SLC6A4HSD17B10SIGMAR1LMNA | |
| SCHEMBL4411875 | 0.81 | DPP7 (0.44) | SLC6A4HSD17B10PLAUPLAURMAPT | |
| SCHEMBL9267853 | 0.81 | DPP7 (0.40) | SLC6A4HSD17B10PLAUPLAURMAPT | |
| SCHEMBL14774780 | 0.80 | MAPT (0.48) | HSD17B10PLAUPLAURSIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-10-24 | — | — | US | claimed |
| EP-3568205-B1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | RADIOMEDIX INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023091689-A1 | COMBINED USE OF MCR1-DIRECTED RADIOTHERAPY AND IMMUNE CHECKPOINT INHIBITION IN THE TREATMENT OF MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11576987-B2 | Compositions and methods of treating melanoma | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11541133-B2 | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes | RADIOMEDIXINC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210373011-A1 | COMPOSITIONS AND METHODS FOR HIGH-SENSITIVITY IMMUNOASSAYS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-11179484-B2 | Compositions and methods of treating melanoma | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3568205-A1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | Radiomedix Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190336623-A1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | ORANO MED (FR) | 2019-11-07 | — | — | US | disclosed |
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018132751-A1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | RADIOMEDIX INC. (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-2018027221-A1 | COMPOSITIONS AND METHODS FOR HIGH-SENSITIVITY IMMUNOASSAYS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541133-B2 | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes | SSTR1, SSTR2, SSTR5 | OPRD1 348/4885SLC6A4 2444/4885HSD17B10 4671/4885 |
| US-20190336623-A1 | TREATMENT OF CANCER CELLS OVEREXPRESSING SOMATOSTATIN RECEPTORS USING OCREOTIDE DERIVATIVES CHELATED TO RADIOISOTOPES | SSTR1, SSTR2, SSTR5 | OPRD1 348/4885SLC6A4 2444/4885HSD17B10 4671/4885 |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | OPRD1 3770/4885SLC6A4 4788/4885HSD17B10 3659/4885 |
| US-11576987-B2 | Compositions and methods of treating melanoma | MC1R, TIE1, RB1 | OPRD1 3770/4885SLC6A4 4791/4885HSD17B10 3648/4885 |
| US-20190321495-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, MKI67 | OPRD1 3630/4885SLC6A4 4766/4885HSD17B10 3323/4885 |
| US-11179484-B2 | Compositions and methods of treating melanoma | MC1R, TIE1, MKI67 | OPRD1 3630/4885SLC6A4 4766/4885HSD17B10 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.